Compare FBGL & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBGL | NOTV |
|---|---|---|
| Founded | 1996 | 1974 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 10.8M |
| IPO Year | N/A | 1997 |
| Metric | FBGL | NOTV |
|---|---|---|
| Price | $0.57 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 691.8K | 391.2K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 49.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $547,656,000.00 |
| Revenue This Year | N/A | $5.28 |
| Revenue Next Year | N/A | $5.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 511.19 |
| 52 Week Low | $0.34 | $0.24 |
| 52 Week High | $1.40 | $3.31 |
| Indicator | FBGL | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 39.14 |
| Support Level | $0.47 | $0.26 |
| Resistance Level | $0.74 | $0.46 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 21.89 | 15.67 |
FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.